Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect In Pancreatic Murine Tumor Models At ESTRO 2024 Congress In Glasgow; Initial Data Demonstrates Reduction In Distant Pancreatic Cancer Tumor Growth Rate Starting From 3-Weeks...
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect In Pancreatic Murine Tumor Models At ESTRO 2024 Congress In Glasgow; Initial Data Demonstrates Reduction In Distant Pancreatic Cancer Tumor Growth Rate Starting From 3-Weeks...
Alpha Tau在格拉斯哥的ESTRO 2024大会上公布了临床前数据，表明胰腺鼠肿瘤模型的腹腔免疫效应；初步数据显示，从3周开始，远距离胰腺癌肿瘤的生长速度会降低...
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect In Pancreatic Murine Tumor Models At ESTRO 2024 Congress In Glasgow; Initial Data Demonstrates Reduction In Distant Pancreatic Cancer Tumor Growth Rate Starting From 3-Weeks After First Tumor Is Treated With Alpha Dart Alone
Alpha Tau在格拉斯哥的ESTRO 2024大会上公布了临床前数据，显示胰腺鼠肿瘤模型的腹腔免疫效应；初步数据显示，从单独使用Alpha Dart治疗第一个肿瘤后的3周开始，远距离胰腺癌肿瘤的生长率会降低
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone
-初步数据显示，从单独使用Alpha Dart治疗第一个肿瘤后的三周开始，远端胰腺癌肿瘤的生长率显著降低
- Effect seen across both Panc02 and KPC tumor models -
-在 Panc02 和 KPC 肿瘤模型中均可见效果-
JERUSALEM, May 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))))), the developer of the innovative alpha-radiation cancer therapy...
耶路撒冷，2024年5月6日（环球通讯社）——创新...
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。